Found: 5
Select item for more details and to access through your institution.
Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients.
- Published in:
- British Journal of Haematology, 2018, v. 183, n. 1, p. 60, doi. 10.1111/bjh.15504
- By:
- Publication type:
- Article
Population-Based External Validation of the EASIX Scores to Predict CAR T-Cell-Related Toxicities.
- Published in:
- Cancers, 2023, v. 15, n. 22, p. 5443, doi. 10.3390/cancers15225443
- By:
- Publication type:
- Article
The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The Netherlands.
- Published in:
- Cancers, 2023, v. 15, n. 17, p. 4334, doi. 10.3390/cancers15174334
- By:
- Publication type:
- Article
CD38 and CD45 expression on plasma cells and response to daratumumab in Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e164, doi. 10.1016/j.clml.2019.09.274
- By:
- Publication type:
- Article
Identifying clinical response to daratumumab therapy in relapsed/refractory multiple myeloma using a patient‐derived in vitro model.
- Published in:
- EJHaem, 2024, v. 5, n. 1, p. 141, doi. 10.1002/jha2.824
- By:
- Publication type:
- Article